|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Hematology, Oncology, and Tumor
Immunology, Robert Rössle Cancer Center, Charité,
Humboldt-University of Berlin, Germany; HELIOS Klinikum Berlin,
Germany; and the Department of Pediatrics, Medical School of Hannover,
Germany.
Within childhood T-cell acute lymphoblastic leukemia (T-ALL),
patients with a cortical (CD1a+) immunophenotype have been
identified as a subgroup with favorable outcome in the acute
lymphoblastic leukemia-Berlin-Frankfurt-Münster (ALL-BFM),
Cooperative study group for childhood acute lymphoblastic leukemia
(COALL) and Pediatric Oncology Group studies. We investigated in leukemic samples of children with T-ALL (n = 81) whether the different in vivo therapy response could be linked to differential in
vitro susceptibility to apoptotic cell death. The extent of dexamethasone- as well as doxorubicin-induced apoptosis, detected by
annexin V staining, positively correlated with the expression levels of
CD1a (Spearman correlation coefficient, rs = 0.3 and 0.4, respectively; P < .01). When compared to cortical T-ALL, mature (CD1a Precursor T-cell acute lymphoblastic leukemia
(T-ALL), which accounts for approximately 15% of all childhood acute
leukemias, has been reported to have a worse prognosis than precursor
B-cell ALL.1,2 However, within T-ALL a heterogeneous
therapeutic response has been observed and, in recent years,
immunophenotypic studies identified CD markers whose expression
patterns distinguish prognostic subgroups in childhood T-ALL. T-ALL
patients with a cortical (CD1a+) immunophenotype were
identified as a subgroup with favorable outcome in the acute
lymphoblastic leukemia-Berlin-Frankfurt-Münster (ALL-BFM)
study,3 in the Cooperative study group for childhood acute
lymphoblastic leukemia (COALL) study trial,4 and the Pediatric Oncology Group study.5 CD2+
T-ALL had a better 5-year event-free survival compared to
CD2 Because chemotherapeutic treatment might induce cell death by
different apoptotic signaling pathways,8-10 it can be
speculated that these immunophenotypically defined prognostic T-ALL
subgroups differ in their susceptibility to chemotherapy-induced
apoptosis. However, there are few experimental data on the in vitro
accessibility to apoptotic programs within prognostic T-ALL subtypes.
Within the Dutch Childhood Leukemia Study Group (DCLSG) study,
positivity for peanut agglutinin binding as a prognostic favorable
marker in T-ALL has been analyzed in context of immunophenotype and
drug sensitivity in vitro.11 Peanut agglutinin binding did
not correlate with maturation stage and in vitro prednisone
sensitivity, although a correlation with prednisone response in vivo
has been observed. Here, we investigated the apoptotic response to
dexamethasone and doxorubicin in immunophenotypically defined T-ALL
subtypes as well as a series of T-ALL cell lines. Leukemic cells were
further examined with respect to several common apoptosis-related
features: expression of Bax, Bcl-2, and CD95, extent of spontaneous
apoptosis in vitro, and susceptibility to CD95-induced apoptosis.
Interleukin 7 (IL-7)-mediated signaling, suggested to reflect distinct
developmental stages and differences in the accessibility to apoptotic
programs in childhood T-ALL,12 was used as a tool to
investigate drug-induced apoptotic pathways in T-ALL. Finally, the
relationship between in vitro sensitivity to drug-induced cell death
and response to initial prednisone treatment and induction chemotherapy
in vivo for childhood T-ALL cases enrolled in the ALL-BFM study trials was determined.
Patient population
Freshly obtained leukemic blasts were purified either from bone marrow
(BM) or peripheral blood (PB) patient samples by density gradient
centrifugation. Viability of cells was always more than 90% as
determined by trypan blue or propidium iodide (PI) (Sigma, Deisenhofen,
Germany) exclusion. All samples contained more than 90% leukemic cells
based on morphologic and immunophenotypic criteria. Most of the
patients investigated were enrolled in the multicenter ALL-BFM
study.2,17 Therapy of the patients in the first 14 days
consisted of intrathecal methotrexate (on day 1), prednisone (daily, in
rapidly increasing dose from day 1), vincristine and daunorubicin (on
day 8), and asparaginase (on day 12).18 In the present in
vitro study, glucocorticoids and anthracyclines were represented by
dexamethasone and doxorubicin, respectively. The structurally related
dexamethasone and prednisone19-21 as well as doxorubicin
and daunorubicin20,22 reveal reportedly high levels of in
vitro cross-resistance in acute leukemia.
Human leukemia cell lines of T-ALL origin (KE-37, MOLT-3, P12/Ichikawa,
BE-13, Peer, Jurkat, PF-382, CCRF-CEM) used in the study were obtained
from the DSM Cell Culture Bank (Braunschweig, Germany). All cultures
were free of Mycoplasma contaminations as assessed by
Mycoplasma PCR Primer Set kit (Stratagene, Amsterdam, The Netherlands).
Cell culture
Assessment of apoptosis To determine the extent of apoptosis, cells were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V and PI using the annexin V kit (Beckman Coulter) as previously described.12,23 Thereafter, samples were analyzed by flow cytometry (FACScan, Becton Dickinson, San Jose, CA) for the presence of viable (annexin V and PI), early apoptotic
(annexin V+, PI), and late
apoptotic/secondary necrotic (annexin V and
PI+) cells.
The extent of apoptosis (N%) was quantified as percentage of annexin
V+ cells as previously described.12,23 The
extent of spontaneous apoptosis was calculated as difference of N%
values in leukemic samples following and prior to culture in medium,
Assessment of IL-7 effects As previously described, the rescue of leukemic cells from spontaneous apoptosis by IL-7 was evaluated as difference NIL-7 between the extent of apoptosis after
culturing in the absence and presence of IL-7.12
The extent of the drug-specific apoptosis in the presence of IL-7 (in
percent) was calculated by the formula:
Assessment of cell cycle distribution To study cell cycle distributions, cells were fixed and stained as described elsewhere.12 Briefly, a pellet of 2 × 105 cells was fixed by adding 2 mL ice-cold 70% ethanol for at least one hour at 4°C. After washing, the cells were resuspended in 0.5 mL phosphate-buffered saline containing 50 µg/mL PI, pH 7.5. Following the treatment with 10 µL 10 mg/mL RNase (type I-A; Boehringer Mannheim, Mannheim, Germany) for 30 minutes at room temperature in the dark, the cells were stored at 4°C until flow cytometric analysis. Cell cycle analysis was carried out using either CellQuest (Becton Dickinson) or ModFit LT (Verity, Topsham, ME) software.Assessment of CD95, Bcl-2, and Bax expression Expression of the apoptosis-related molecules CD95, Bcl-2, and Bax was assessed as previously described.12,23 Briefly, surface CD95 expression was determined using the phycoerythrin-conjugated anti-CD95 monoclonal antibody (clone DX2, Pharmingen, San Diego, CA). To evaluate expression of the intracellular proteins Bcl-2 and Bax, leukemic cells were fixed and permeabilized using the fixation-permeabilization kit (Fix & Perm; An-der Grub, Kaumberg, Austria) as recommended by the manufacturer. Bcl-2 antigen was detected by the FITC-conjugated anti-Bcl-2 antibody clone 124 (Dako, Glostrup, Denmark). FITC-conjugated irrelevant mouse antibodies of the appropriate immunoglobulin isotype (Beckman Coulter) were used as negative controls. Bax has been detected by Bax-specific rabbit polyclonal antibodies raised against synthetic peptide sequences (I-19, Santa Cruz Biotechnology, Santa Cruz, CA). FITC-conjugated goat antirabbit serum (Medac, Hamburg, Germany) as a secondary staining reagent was used. For negative control, cells were stained with Bax antibody in the presence of the blocking synthetic peptide (provided by the manufacturer, Santa Cruz Biotechnology) at saturation conditions (10 µg peptide versus 1 µg antibody) as determined from peptide titration experiments (data not shown).Immunofluorescence analysis was performed on a FACScan. The expression of antigens was quantified by flow cytometry in molecules of equivalent soluble fluorochrome (MESF) units using calibration beads as fluorescence standards (Dako) as previously described.12 Statistical analysis Mean values are given as mean ± SEM or SD. Differences (P values) were evaluated using the 2-tailed nonparametric Mann-Whitney test for continuous variables and the Fisher exact test for categorical variables. Associations of protein expression levels, extent of spontaneous and chemotherapy-induced apoptosis, IL-7 rescue, as well as percentages of blast cells in BM were evaluated using bivariate nonparametric Spearman correlation statistics. Differences were considered significant for P < .05. Statistical analysis was performed using the SPSS software.
In vitro susceptibility to drug-induced apoptosis in primary T-ALL A series of 81 primary T-ALL cell samples were tested for susceptibility to dexamethasone- and doxorubicin-induced apoptosis. First, dose dependence of dexamethasone- and doxorubicin-induced apoptosis was analyzed in 12 and 47 T-ALL samples, respectively. In these experiments, in vitro incubation periods of 24 hours were found to be optimal because, after longer incubation periods, the cases with high rates of spontaneous or drug-induced apoptosis could not be evaluated. On the other hand, shorter periods were often not sufficient to induce apoptosis. In dexamethasone-treated cells, either dose-dependent apoptosis (n = 9) or total resistance (n = 3) in the whole concentration range (0.2-50 µM) has been observed. In the responding samples, 2 µM dexamethasone was sufficient to induce maximal drug response, and this concentration has been further used to characterize the whole T-ALL series. With respect to doxorubicin, almost all samples (45 of 47) disclosed dose-dependent apoptosis (mean percent of drug-specific apoptosis ± SEM: 11.5% ± 1.6%, 46.7% ± 4.5%, and 68.7% ± 4.1% at 0.2 µM, 1 µM, and 5 µM of doxorubicin, respectively). At 1 µM doxorubicin, the maximal heterogeneity between individual samples and, consequently, the best interindividual resolution has been observed (as also indicated by the highest value of SD: 31% at 1 µM doxorubicin versus 11% and 28% at 0.2 µM and 5 µM doxorubicin, respectively). Using these data, the whole series of T-ALL has been characterized by the response to the drugs at optimal concentrations. T-ALL samples disclosed highly heterogeneous response to both drugs (mean values of drug-specific apoptosis ± SEM: 39.2 ± 3.6 and 37.8 ± 3.1 for doxorubicin and dexamethasone, respectively; Figure 1A). No clear-cut correlation between dexamethasone- and doxorubicin-specific apoptosis in individual T-ALL samples has been observed (Spearman correlation coefficient, rs = 0.22, P = .053; Figure 1A).
In vitro susceptibility to drug-induced apoptosis in context of immunophenotype and maturation stage Within T-ALL, CD1a and sCD3 antigens are the most important immunophenotypic markers used to define cortical and mature T-ALL according to the EGIL classification.16 These markers were differently associated with the susceptibility to doxorubicin- and dexamethasone-induced cell death; both kinds of apoptosis correlated significantly with the expression levels of CD1a, whereas sCD3 expression was associated with the dexamethasone-induced apoptosis only (Table 1). Consequently, statistically significant differences have been observed between immunophenotypically defined T-ALL subgroups (Figure 1B,C). Cortical T-ALLs were more susceptible to doxorubicin-induced apoptosis as compared with immature pro-/pre-T-ALL (P = .02) and mature T-ALL (P = .02). Pro-/pre-T-ALL and mature T-ALL did not differ significantly in their susceptibility to doxorubicin-induced cell death (P = .92). With respect to dexamethasone-induced cell death, cortical T-ALL was also more susceptible compared with pro-/pre-T-ALL (P = .002). Mature T-ALL did not reveal significantly different susceptibility to dexamethasone-induced apoptosis as compared with pro-/pre-T-ALL (P = .23) and cortical T-ALL (P = .25).
In vitro susceptibility to drug-induced apoptosis in context of early cytoreduction in vivo A poor in vivo response to initial glucocorticoid treatment (defined as > 1000/µL blasts in PB on day 8) has been shown to be a strong adverse prognostic parameter in the ALL-BFM trials.2,17,18 In our study, data on responses to initial therapy were available for 63 T-ALL samples, with the subtype distribution similar to that in the whole series of 81 patients: 13 pro-/pre-T-ALL, 38 cortical T-ALL, and 12 mature T-ALL. Good responders (36 of 63) showed a better susceptibility to dexamethasone and to doxorubicin than poor responders (27 of 63; mean percent of apoptosis ± SEM: 43% ± 4% versus 34% ± 6% and 49% ± 5% versus 34% ± 6% for dexamethasone and doxorubicin, respectively). However, only for doxorubicin did the difference between poor and good responder achieve a borderline significance (Mann-Whitney test, P = .052). For dexamethasone, statistical significance could be achieved by using 10% cutoff levels for drug-specific apoptosis: T-ALL cases with dexamethasone sensitivity higher than 10% were more often good responders to prednisone treatment (32 of 49) as compared to cases with the lower sensitivity (4 of 14) (95% CI for odd ratios, 1.3-17.3; Fisher exact test, P = .03).In addition to the good/poor prednisone response criterion in PB
at day 8, early response to initial therapy can be characterized by
percentage of blast cells in BM at day 15 (data available for 51 patients; distribution between T-ALL subgroups similar to that in the
whole series of n = 63). As expected, percentages of blast cells in
BM at day 15 were highly associated with prednisone response (Mann-Whitney test, P = .000). Interestingly,
susceptibility to dexamethasone (but not to doxorubicin) correlated
closely with the early cytoreduction characterized by the day 15 criterion (rs =
In vitro susceptibility to drug-induced apoptosis in context of apoptosis-related parameters To identify factors that might be responsible for the differential drug sensitivity in leukemic cells, we examined intracellular expression levels of apoptosis-regulating Bcl-2 and Bax proteins (n = 58) as well as surface expression and function of CD95 death receptor (n = 54). Furthermore, spontaneous apoptosis (n = 81) and cell rescue from spontaneous apoptosis by IL-7 (77 patients investigated; 4 samples could not be evaluated because of the absence of spontaneous apoptosis) were also examined. There were no statistically significant correlations between drug-induced cell death and Bcl-2 family-related as well as CD95-related parameters (Table 1). By contrast, there was a statistically significant association between the rate of spontaneous apoptosis in vitro with both doxorubicin- and dexamethasone-induced apoptosis (Table 1). Most interestingly, the extent of cell rescue from spontaneous apoptosis by IL-7 (IL-7 rescue) was highly associated with dexamethasone- but not with doxorubicin-induced apoptosis (Table 1). IL-7 rescue has been previously shown to correlate with the expression of CD1a and sCD3.12 Also in the present series, IL-7 rescue was significantly higher in CD1a+ versus CD1a and
in sCD3+ versus sCD3 T-ALL samples
(Mann-Whitney test, P = .019 and .009, respectively). It
was, therefore, possible that the observed association between dexamethasone and IL-7 effects in T-ALL was a reflection of the correlation between IL-7 rescue and immunophenotype. Therefore, we
analyzed the relationship between dexamethasone-specific apoptosis and
IL-7 rescue within CD1a+ or sCD3+ T-ALL as well
as CD1a or sCD3 T-ALL. Within these T-ALL
subgroups, dexamethasone-induced apoptosis remained associated with
IL-7 rescue (rs values between 0.31 and 0.44, P < .05).
Modulation of drug-induced apoptosis by IL-7 In T-ALL, IL-7-mediated signaling has been recently demonstrated to interfere with spontaneous apoptosis.12 In the present study, we investigated interference of IL-7 signaling with drug effects in T-ALL cell lines (Figure 3) and primary T-ALL (Figure 4).
The T-ALL cell lines heterogeneously responded to doxorubicin (range of drug-specific apoptosis 12%-100%). In the majority of T-ALL cell lines, doxorubicin-induced apoptosis has not been influenced by coincubation with IL-7 (data not shown). However, IL-7 was able to inhibit apoptosis in KE-37 cells (Figure 3). Moreover, IL-7 enhanced doxorubicin-induced apoptosis (MOLT-3 cells, Figure 3), thus demonstrating a principal possibility of antiapoptotic and proapoptotic modulation of the drug-induced apoptosis by IL-7 in T-ALL. With respect to dexamethasone, most of the cell lines were dexamethasone resistant, in striking difference to the primary T-ALL cells. In 2 cell lines only, P12/Ichikawa (data not shown) and KE-37 (Figure 3), low levels of apoptosis could be observed after extended incubation periods (48 hours). Furthermore, only these 2 cell lines were also susceptible to dexamethasone in terms of cell cycle perturbations (G0/G1 phase accumulation, data not shown). In both cell lines, IL-7 was able to inhibit dexamethasone-specific apoptosis but did not reverse cell accumulation in G0/G1 phase (Figure 3 and data not shown). The effect of IL-7 on doxorubicin-induced apoptosis was investigated in 16 primary T-ALL samples (Figure 4). In 12 of the 16 samples examined, IL-7 was able to inhibit drug-induced apoptosis to different extents. Notably, we did not observe proapoptotic effects of IL-7 in primary leukemic cells. The effect of IL-7 on dexamethasone-induced apoptosis was studied in 46 primary T-ALLs. In most of the samples IL-7 strongly reduced dexamethasone-induced apoptosis (Figure 4). Similarly to the doxorubicin-treated cells, proapoptotic effects of IL-7 in the dexamethasone-treated primary leukemic cells have not been observed.
Immunophenotypically defined T-ALL subgroups differ in their response to chemotherapy. Because these differences are supposed to be due to their distinct sensitivities to drug-induced apoptosis, we determined the in vitro susceptibility to dexamethasone- and doxorubicin-induced cell death of prognostic T-ALL subgroups. Furthermore, we addressed apoptotic mechanisms underlying chemotherapy-induced cell death in T-ALL. CD1a+ T-ALL, previously shown as a prognostically favorable subgroup in 3 representative and independent clinical trials,3-5 disclosed in our study an increased in vitro susceptibility to both dexamethasone- and doxorubicin-induced cell death, compared with pro-/pre-T-ALL as well as mature T-ALL. The observed maturation-dependent difference may reflect a generally higher susceptibility to chemotherapy-induced cell death in cortical T-ALL. Thymocytes in the thymic cortex are extremely sensitive to glucocorticoid-induced cell death; even the physiologic concentrations achieved during a stress response can be sufficient to cause their apoptosis.24 Based on clinical data, Niehues et al4 suggested that cortical T-ALL cells may possess the higher apoptosis susceptibility characteristic of normal cortical thymocytes. Our study provides in vitro evidence supporting this hypothesis. In context of clinical data, doxorubicin-induced apoptosis disclosed low levels of correlation with early cytoreduction parameters, thus indicating that in vitro anthracycline sensitivity reflects rather an overall than drug-specific susceptibility of leukemic cells to chemotherapeutic treatment in vivo. Application of a broad spectrum of anticancer drugs might be expected to improve the clinical impact of the in vitro apoptosis testing. However, a generally limited cell number in leukemia samples could hamper the effectiveness of this approach. With respect to dexamethasone-induced apoptosis, the observed relatively strong correlation with percentages of blast cells in BM at day 15 is a quite interesting observation, which points to a clinical relevance of this parameter. However, prednisone response in PB at day 8 (being strongly correlated with percentages of blast cells at day 15) revealed only a borderline correlation with the dexamethasone sensitivity. The reason for this difference is unknown, but it is tempting to speculate that it might reflect (time-dependent) differences of cytoreduction in BM and in PB during initial therapy. Molecular mechanisms and factors responsible for differential sensitivity to drug treatment in ALL remain to be elucidated. Constitutive CD95 and Bcl-2 expression levels as well as CD95 function did not predict in vivo treatment response in childhood T-ALL.25,26 In the present study, we also did not observe associations between these parameters and the in vitro susceptibility to apoptosis, indicating that other intracellular checkpoints might be more important for resistance to chemotherapy-induced apoptosis in T-ALL. Recently, we characterized childhood T-ALL cells with respect to their cytokine responsiveness in terms of modulation of spontaneous apoptosis in vitro.12 A strong inhibition of spontaneous apoptosis by coincubation with IL-7 was associated with CD1a and sCD3 expression and a better early cytoreduction in vivo. IL-7 rescue was suggested to be a surrogate marker reflecting differential survival factor dependence, apoptosis regulation, and treatment response in maturation-dependent T-ALL subgroups.12 In the current study, we investigated the effect of IL-7 on drug-induced apoptosis in childhood T-ALL. Recently, IL-7 has been reported to enhance cytotoxicity of cytarabine and thioguanine, and, in individual cases, to decrease cytotoxicity of prednisolone in ALL.27 In T-ALL cell lines, we also observed proapoptotic and antiapoptotic effects of IL-7; however, only an antiapoptotic effect of IL-7 was observed in primary T-ALL. This finding is in line with an up-regulation of Bcl-2 in IL-7-treated T-ALL cells as previously reported,12,28 and indicates that dexamethasone- and doxorubicin-induced apoptosis might use common checkpoints at the level of Bcl-2 protein family. On the other hand, the absence of correlation between susceptibilities to doxorubicin and dexamethasone in individual T-ALL samples points to largely differential pathways triggered by these drugs. Glucocorticoids are principal agents in ALL therapy and
identification of their signaling pathways in primary leukemic cells is
of particular interest. In our study, dexamethasone and IL-7 effects
were strongly associated in individual T-ALL samples. Given the
previously observed association of the IL-7 rescue in vitro with
glucocorticoid response in vivo,12 these data indicate that pathways triggered by IL-7 and glucocorticoids might be closely related in T-ALL cells. Glucocorticoids exert their biologic activity via ligation of glucocorticoid receptors (GRs), which may act directly
as transcription factors. Steroid-inducible proapoptotic genes,
however, have not yet been identified.24 Alternatively, glucocorticoid-activated GRs may exert considerable cross-reactivity with other transcription factors and modify their biologic
activity.24 Cross-reaction of glucocorticoids with
transcriptional regulators, responsible for the survival of target
cells, would therefore result in induction of apoptosis. Transcription
factor nuclear factor- In vitro chemosensitivity testing by methyl-thiazol-tetrazolium (MTT) assay using a broad spectrum of cytotoxic drugs has proved to be a valuable prognostic marker for therapy response in childhood ALL.39,40 Using the MTT assay, a positive correlation between in vitro and in vivo response to prednisone treatment has been observed in childhood ALL.20 Within ALL, T-ALL cells were generally more resistant to a variety of cytotoxic drugs including glucocorticoids and anthracyclines as compared to common and pre-B-ALL.41-43 However, subtype-specific differences within T-ALL have not yet been reported. In our study, the annexin V-based testing provided useful information on maturation-dependent differences in the apoptotic behavior of leukemic cells within T-ALL and revealed significant in vitro-in vivo correlations. Thus, the flow cytometric annexin V method seems to be a valuable tool for the chemosensitivity assessment of acute leukemia cells. The long-term follow-up of the examined patients will show whether the investigated apoptosis parameters could also contribute to predict overall therapy outcome in childhood T-ALL. In conclusion, our data show maturation-dependent differences in the in vitro susceptibility to dexamethasone and doxorubicin in childhood T-ALL. The enhanced sensitivity to both drugs in cortical T-ALL might account for the better in vivo treatment response of this prognostically favorable T-ALL subgroup. The in vitro assessment of apoptotic features of drug cytotoxicity provides further insights in chemotherapy-induced leukemic cell death, which might be useful for the development of specific tailored in vivo chemotherapy regimens in the future.
We would like to thank G. Czerwony, K. Ganzel, M. Martin, and K. Liebezeit for their excellent technical assistance. I. Krämer and C. Witt were most helpful with clinical data management. The cell samples included in this study were sent from various hospitals in Germany participating in the ongoing ALL-BFM trials. We thank all clinicians providing cell samples for our investigations.
Submitted June 5, 2001; accepted January 24, 2002.
Supported by grants of the "Deutsche José Carreras Leukämie-Stiftung" (JCLS 1998/NAT-3 to C.W.), the "Deutsche Leukämie-Forschungshilfe" (DLFH-98.04 to V.R.) and the "Monika Kutzner-Stiftung."
C.W. and V.R. equally contributed to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Leonid Karawajew, Robert-Rössle-Clinic, Charité, Humboldt University of Berlin, Lindenberger Weg 80, 13125 Berlin, Germany; e-mail: karawajew{at}rrk-berlin.de.
1.
Uckun FM, Sensel MG, Sun L, et al.
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.
Blood.
1998;91:735-746
2.
Reiter A, Schrappe M, Ludwig WD, et al.
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86.
Blood.
1994;84:3122-3133 3. Ludwig WD, Harbott J, Bartram CR, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res. 1993;131:269-282[Medline] [Order article via Infotrieve]. 4. Niehues T, Kapaun P, Harms DO, et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999;13:614-617[CrossRef][Medline] [Order article via Infotrieve]. 5. Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL: a Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696-1707[CrossRef][Medline] [Order article via Infotrieve].
6.
Uckun FM, Steinherz PG, Sather H, et al.
CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study.
Blood.
1996;88:4288-4295
7.
Pui CH, Behm FG, Singh B, et al.
Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia.
Blood.
1990;75:174-179 8. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49[CrossRef][Medline] [Order article via Infotrieve]. 9. Houghton JA. Apoptosis and drug response. Curr Opin Oncol. 1999;11:475-481[CrossRef][Medline] [Order article via Infotrieve].
10.
Wickremasinghe RG, Hoffbrand AV.
Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies.
Blood.
1999;93:3587-3600 11. Kaspers GJ, Veerman AJ, Van Wering ER, et al. Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia. Leukemia. 1996;10:675-681[Medline] [Order article via Infotrieve].
12.
Karawajew L, Ruppert V, Wuchter C, et al.
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia.
Blood.
2000;96:297-306 13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458[Medline] [Order article via Infotrieve].
14.
Ludwig WD, Rieder H, Bartram CR, et al.
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89.
Blood.
1998;92:1898-1909
15.
Creutzig U, Harbott J, Sperling C, et al.
Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Blood.
1995;86:3097-3108 16. Béné MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786[Medline] [Order article via Infotrieve].
17.
Dordelmann M, Reiter A, Borkhardt A, et al.
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Blood.
1999;94:1209-1217
18.
Schrappe M, Reiter A, Ludwig WD, et al.
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group.
Blood.
2000;95:3310-3322 19. Kaspers GJ, Veerman AJ, Popp Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:114-121[CrossRef][Medline] [Order article via Infotrieve].
20.
Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does Van Den Berg A, Veerman AJ.
Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.
Blood.
1998;92:259-266 21. Ito C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2370-2376[Abstract]. 22. Kaspers GJ, Kardos G, Pieters R, et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia. 1994;8:1224-1229[Medline] [Order article via Infotrieve]. 23. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia. 1999;13:1943-1953[CrossRef][Medline] [Order article via Infotrieve]. 24. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309-345[CrossRef][Medline] [Order article via Infotrieve]. 25. Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110:154-160[CrossRef][Medline] [Order article via Infotrieve].
26.
Uckun FM, Yang Z, Sather H, et al.
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Blood.
1997;89:3769-3777 27. Duyn AE, Kaspers GJ, Pieters R, et al. Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. Ann Hematol. 1999;78:163-171[CrossRef][Medline] [Order article via Infotrieve].
28.
Barata JT, Cardoso AA, Nadler LM, Boussiotis VA.
Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Blood.
2001;98:1524-1531 29. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF- kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14:399-402[CrossRef][Medline] [Order article via Infotrieve]. 30. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAILreceptors gene expression and constitutive NF-kB activity. Leukemia. 2001;15:921-928[CrossRef][Medline] [Order article via Infotrieve].
31.
Nissen RM, Yamamoto KR.
The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain.
Genes Dev.
2000;14:2314-2329 32. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 1997;16:4698-4707[CrossRef][Medline] [Order article via Infotrieve].
33.
Wissink S, van Heerde EC, Schmitz ML, et al.
Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor.
J Biol Chem.
1997;272:22278-22284
34.
Banerjee A, Rothman P.
IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling.
J Immunol.
1998;161:4611-4617
35.
Chene L, Nugeyre MT, Guillemard E, Moulian N, Barre Sinoussi F, Israel N.
Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7.
J Virol.
1999;73:7533-7542
36.
Chene L, Nugeyre MT, Barre Sinoussi F, Israel N.
High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells.
J Virol.
1999;73:2064-2073
37.
Ward AC, Touw I, Yoshimura A.
The Jak-Stat pathway in normal and perturbed hematopoiesis.
Blood.
2000;95:19-29 38. Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331-334[CrossRef][Medline] [Order article via Infotrieve].
39.
Kaspers GJ, Veerman AJ, Pieters R, et al.
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Blood.
1997;90:2723-2729 40. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399-403[CrossRef][Medline] [Order article via Infotrieve].
41.
Pieters R, den Boer ML, Durian M, et al.
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia 42. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma. 1995;19:407-416[Medline] [Order article via Infotrieve]. 43. Pieters R, Kaspers GJ, van Wering ER, et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:392-397[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Baleydier, A.-V. Decouvelaere, J. Bergeron, P. Gaulard, D. Canioni, Y. Bertrand, S. Lepretre, B. Petit, H. Dombret, K. Beldjord, et al. T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome Clin. Cancer Res., February 1, 2008; 14(3): 692 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Breit, M. Stanulla, T. Flohr, M. Schrappe, W.-D. Ludwig, G. Tolle, M. Happich, M. U. Muckenthaler, and A. E. Kulozik Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia Blood, August 15, 2006; 108(4): 1151 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Karawajew, P. Rhein, G. Czerwony, and W.-D. Ludwig Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species Blood, June 15, 2005; 105(12): 4767 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Barata, V. A. Boussiotis, J. A. Yunes, A. A. Ferrando, L. A. Moreau, J. P. Veiga, S. E. Sallan, A. T. Look, L. M. Nadler, and A. A. Cardoso IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL Blood, March 1, 2004; 103(5): 1891 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Cave, S. Suciu, C. Preudhomme, B. Poppe, A. Robert, A. Uyttebroeck, M. Malet, P. Boutard, Y. Benoit, L. Mauvieux, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951 Blood, January 15, 2004; 103(2): 442 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. I. Brown, J. Fang, K. Alcorn, R. Barr, J. M. Kim, R. Wasserman, and S. A. Grupp Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling PNAS, December 9, 2003; 100(25): 15113 - 15118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kim, J. Fang, S. Rheingold, R. Aplenc, R. Wasserman, and S. A. Grupp Cytoplasmic {micro} Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia Cancer Res., August 1, 2002; 62(15): 4212 - 4216. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
0.46, P = .001). Taken
together, the in vitro assessment of drug-induced apoptosis revealed
maturation-dependent differences within childhood T-ALL. The enhanced
sensitivity to both drugs in cortical T-ALL might account for the
better in vivo treatment response of this prognostically favorable
T-ALL subgroup.
(Blood. 2002;99:4109-4115)
B (NF-
implications for treatment of infants.
Leukemia.
1998;12:1344-1348